 A number of non-pharmaceutical interventions aimed at prevention, early identification and slowing progression in Alzheimer's Disease (AD) have emerged (1).
 A recent review has identified weaknesses in existing models for economic evaluation of such interventions. In particular, such models employ short time frames and utilise old transition probabilities (2).
 A probabilistic Markov model was developed to represent the progression of the Danish population of 65 year old males and females from 'no AD' to different stages of the disease (Fig. 1 ).
 The Markov states are presented in Figure 1 .  The model accurately predicted agespecific prevalence of dementia in Denmark (Fig. 2) as well as the distribution of severity of AD in 5-year age groups (not shown).  Uncertainly in input parameters had a higher impact on cost than effect estimates (Fig. 3) . One way sensitivity analyses (data not shown) indicated strong sensitivity to AD-stage progressions, and low sensitivity to utility and cost estimates.  Disease progression data utilised in the model was based on US estimates (Table 1) ; Dirichlet distribution was applied to these estimates.
 Probability of acquiring AD, severityspecific cost and utility data was obtained from Danish reports (Table 2) .  The model was validated by comparing it's ability to predict prevalence of AD to the most recent data available for Denmark, based on a range of cohort studies (4).
 Parameter validity was assessed by sensitivity analyses.
